Gs Investments Inc. acquired a new position in Nektar Therapeutics (NASDAQ:NKTR) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 51,460 shares of the biopharmaceutical company’s stock, valued at approximately $1,006,000.

Several other institutional investors have also recently modified their holdings of the company. Louisiana State Employees Retirement System lifted its stake in shares of Nektar Therapeutics by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock worth $1,236,000 after buying an additional 500 shares during the last quarter. LS Investment Advisors LLC lifted its stake in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 535 shares during the last quarter. World Asset Management Inc lifted its stake in shares of Nektar Therapeutics by 5.6% in the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 539 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 692 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its stake in shares of Nektar Therapeutics by 0.3% in the first quarter. New York State Teachers Retirement System now owns 256,024 shares of the biopharmaceutical company’s stock worth $6,009,000 after buying an additional 800 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

NKTR has been the subject of a number of analyst reports. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price objective on shares of Nektar Therapeutics in a research note on Friday, July 21st. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, August 1st. ValuEngine upgraded shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. William Blair restated an “outperform” rating on shares of Nektar Therapeutics in a research note on Monday, June 26th. Finally, BidaskClub cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $26.80.

In other news, Director Roy A. Whitfield bought 35,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was bought at an average price of $17.95 per share, with a total value of $628,250.00. Following the completion of the acquisition, the director now owns 133,000 shares of the company’s stock, valued at $2,387,350. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Christopher A. Kuebler sold 4,000 shares of Nektar Therapeutics stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $21.86, for a total value of $87,440.00. Following the sale, the director now directly owns 40,500 shares of the company’s stock, valued at approximately $885,330. The disclosure for this sale can be found here. Insiders have sold a total of 539,983 shares of company stock valued at $12,388,528 in the last ninety days. Insiders own 6.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: “51,460 Shares in Nektar Therapeutics (NKTR) Purchased by Gs Investments Inc.” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/51460-shares-in-nektar-therapeutics-nktr-purchased-by-gs-investments-inc/1643461.html.

Nektar Therapeutics (NASDAQ:NKTR) traded down 0.232% during trading on Friday, reaching $23.615. 188,502 shares of the company traded hands. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $25.02. The company’s market cap is $3.69 billion. The company’s 50-day moving average is $22.92 and its 200 day moving average is $20.45.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The business had revenue of $34.60 million for the quarter, compared to analyst estimates of $33.64 million. During the same period in the prior year, the business earned ($0.36) EPS. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. On average, analysts anticipate that Nektar Therapeutics will post ($0.98) earnings per share for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.